A Mutant p53 That Discriminates between p53-Responsive Genes Cannot Induce Apoptosis

REFERENCES

• Baker, S. J., S. Markowitz, E. R. Fearon, J. K. V. Willson, and B. Vogelstein. 1990. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249:912–915.
   PubMed Web of Science ®Google Scholar
• Balkalkin, G., G. Selvanova, T. Yakovleva, E. Kiseleva, E. Kashuba, K. P. Magnusson, L. Szekely, G. Klein, L. Terenius, and K. G. Wiman. 1995. p53 binds single-stranded DNA ends through the C-terminal domain and internal DNA segments via the middle domain. Nucleic Acids Res. 23:362–369.
   PubMedGoogle Scholar
• Barak, Y., E. Gottlieb, T. Juven-Gershon, and M. Oren. 1994. Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. Genes Dev. 8:1739–1749.
   PubMed Web of Science ®Google Scholar
• Bargonetti, J., I. Reynisdottir, P. N. Friedman, and C. Prives. 1992. Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53. Genes Dev. 6:1886–1898.
   PubMed Web of Science ®Google Scholar
• Baserga, R. 1994. Oncogenes and the strategy of growth factors. Cell 79:927–930.
   PubMed Web of Science ®Google Scholar
• Bayle, J. H., B. Elenbaas, and A. J. Levine. 1995. The carboxy-terminal domain of the p53 protein regulates sequence-specific DNA binding through its nonspecific nucleic acid-binding activity. Proc. Natl. Acad. Sci. USA 92:5729–5733.
   PubMed Web of Science ®Google Scholar
• Bissonnette, R. P., F. Exheverri, A. Mahboubi, and D. R. Green. 1992. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature (London) 359:552–554.
   PubMed Web of Science ®Google Scholar
• Brugarolas, J., C. Chandrasekaran, J. I. Gordon, D. Beach, T. Jacks, and G. J. Hannon. 1995. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature (London) 377:552–557.
   PubMed Web of Science ®Google Scholar
• Buckbinder, L., R. Talbott, S. Velasco-Miguel, I. Takenaka, B. Faha, R. Seizinger, and N. Kley. 1995. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature (London) 377:646–649.
   PubMed Web of Science ®Google Scholar
• Caelles, A. M., A. Helmberg, and M. Karin. 1994. p53-dependent apoptosis is not mediated by transcriptional activation of p53-target genes. Nature 370:220–223.
   PubMed Web of Science ®Google Scholar
• Canman, C., E. T. M. Gilmer, S. B. Coutts, and M. B. Kastan. 1995. Growth factor modulation of p53-mediated growth arrest verses apoptosis. Genes Dev. 9:600–611.
   PubMed Web of Science ®Google Scholar
• Chen, X., J. Bargonetti, and C. Prives. 1995. p53, through p21 (WAF1/ CIP1), induces cyclin D1 synthesis. Cancer Res. 55:4257–4263.
   PubMed Web of Science ®Google Scholar
• Chiou, S.-K., L. Rao, and E. White. 1994. Bcl-2 blocks p53-dependent apo-ptosis. Mol. Cell. Biol. 14:2556–2563.
   PubMed Web of Science ®Google Scholar
• Clarke, A. R., C. A. Purdie, D. J. Harrison, R. G. Morris, C. C. Bird, M. L. Hooper, and A. H. Wyllie. 1993. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature (London) 362:849–852.
   PubMed Web of Science ®Google Scholar
• Crook, T., N. Marston, E. Sara, and K. Vousden. 1994. Transcriptional activation by p53 correlates with suppression of growth but not transformation. Cell 79:617–627.
   PubMedGoogle Scholar
• Debbas, M., and E. White. 1993. Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes Dev. 7:546–554.
   PubMed Web of Science ®Google Scholar
• de Jong, D., F. A. Prins, D. Y. Mason, J. C. Reed, G. B. van Ommen, and P. M. Kluin. 1994. Subcellular localization of the bcl-2 protein in malignant and normal lymphoid cells. Cancer Res. 54:256–260.
   PubMed Web of Science ®Google Scholar
• Deng, C., P. Zhang, J. W. Harper, S. J. Elledge, and P. Leder. 1995. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82:675–684.
   PubMed Web of Science ®Google Scholar
• Donehower, L. A., and A. Bradley. 1993. The tumor suppressor p53. Biochim. Biophys. Acta 1155:181–205.
   PubMed Web of Science ®Google Scholar
• Dulic, V., W. K. Kaufman, S. J. Wilson, T. D. Tlsty, E. Lees, J. W. Harper, S. J. Elledge, and S. I. Reed. 1994. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76:1013–1023.
   PubMed Web of Science ®Google Scholar
• El-Deiry, W. S., S. E. Kern, J. A. Pietenpol, K. W. Kinzler, and B. Vogelstein. 1992. Definition of a consensus binding site for p53. Nat. Genet. 1:45–49.
   PubMed Web of Science ®Google Scholar
• El-Deiry, W. S., T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons, J. M. Trent, D. Lin, W. E. Mercer, K. W. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817–825.
   PubMed Web of Science ®Google Scholar
• Eliopoulos, A. G., D. J. Kerr, J. Herod, L. Hodgkins, S. Krajewski, J. C. Reed, and L. S. Young. 1995. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene 11:1217–1228.
   PubMed Web of Science ®Google Scholar
• Fanidi, A., E. A. Harrington, and G. I. Evan. 1992. Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature (London) 359:554–556.
   PubMed Web of Science ®Google Scholar
• Friedlander, P., Y. Legros, T. Soussi, and C. Prives. Regulation of mutant p53 temperature sensitive DNA binding. Submitted for publication.
   Google Scholar
• Friedman, P., S. Scott, B. Vogelstein, and C. Prives. 1990. Wild-type, but not mutant, human p53 proteins inhibit the replication activities of simian virus 40 large tumor antigen. Proc. Natl. Acad. Sci. USA 87:9275–9279.
   PubMedGoogle Scholar
• Ginsberg, D., F. Mechta, M. Yaniv, and M. Oren. 1991. Wild-type p53 can down-modulate the activity of various promoters. Proc. Natl. Acad. Sci. USA 88:9979–9983.
   PubMed Web of Science ®Google Scholar
• Ginsberg, D., D. Michael-Michalovitz, D. Ginsberg, and M. Oren. 1991. Induction of growth arrest by a temperature-sensitive p53 mutant is correlated with increased nuclear localization and decreased stability of the protein. Mol. Cell. Biol. 11:582–585.
   PubMedGoogle Scholar
• Gottlieb, E., R. Haffner, T. von Ruden, E. F. Wagner, and M. Oren. 1994. Down-regulation of wild-type p53 activity interferes with apoptosis of Il-3 dependent hematopoetic cells following Il-3 withdrawal. EMBO J. 13:1368–1374.
   PubMed Web of Science ®Google Scholar
• Gottlieb, E., S. Linder, and M. Oren. 1996. Relationship of sequence-specific transactivation and p53-regulated apoptosis in IL-3-dependent hematopo-etic cells. Cell Growth Differ. 7:301–310.
   PubMedGoogle Scholar
• Gottlieb, T., and M. Oren. 1996. p53 in growth control and neoplasia. Biochim. Biophys. Acta Rev. Cancer 1287:77–102.
   PubMed Web of Science ®Google Scholar
• Graeber, T. G., C. Osmanian, T. Jacks, D. E. Housman, C. J. Koch, S. W. Lowe, and A. J. Giaccia. 1996. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature (London) 379:88–91.
   PubMed Web of Science ®Google Scholar
• Haffner, R., and M. Oren. 1995. Biochemical properties and biological effects of p53. Curr. Opin. Genet. Dev. 5:84–90.
   PubMedGoogle Scholar
• Hall, P. A., P. H. McKee, H. D. P. Menage, R. Dover, and D. P. Lane. 1993. High levels of p53 protein in UV irradiated human skin. Oncogene 8:203–208.
   PubMed Web of Science ®Google Scholar
• Harlow, E., L. V. Crawford, D. C. Pim, and N. M. Williamson. 1981. Monoclonal antibodies specific for simian virus 40 tumor antigens. J. Virol. 39:861–869.
   PubMed Web of Science ®Google Scholar
• Harper, J. W., G. R. Adami, N. Wei, K. Keyomarsi, and S. J. Elledge. 1993. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805–816.
   PubMed Web of Science ®Google Scholar
• Haupt, Y., Y. Barak, and M. Oren. 1996. Cell type specific inhibition of p53-mediated apoptosis by mdm2. EMBO J. 15:1596–1606.
   PubMed Web of Science ®Google Scholar
• Haupt, Y., and M. Oren. p53-mediated apoptosis: mechanisms and regulation. Behring Inst. Res. Commun., in press.
   Google Scholar
• Haupt, Y., S. Rowan, and M. Oren. 1995. p53-mediated apoptosis in HeLa cells can be overcome by excess pRB. Oncogene 10:1563–1571.
   PubMed Web of Science ®Google Scholar
• Haupt, Y., S. Rowan, E. Shaulian, H. Vousden, and M. Oren. 1995. Induction of apoptosis in HeLa cells by trans-activation deficient p53. Genes Dev. 9:2170–2183.
   PubMed Web of Science ®Google Scholar
• Hemerking, H., and D. Eick. 1994. Mediation of c-myc-induced apoptosis by p53. Science 265:2091–2093.
   PubMedGoogle Scholar
• Hockenbery, D. M., G. Nunez, C. Milliman, R. D. Schreiber, and S. J. Korsmeyer. 1990. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature (London) 348:334–336.
   PubMed Web of Science ®Google Scholar
• Hoey, T., R. O. J. Weinzierl, G. Gill, J. Chen, B. D. Dynlacht, and R. Tjian. 1993. Molecular cloning and functional analysis of Drosophila TAF110 reveal properties expected of coactivators. Cell 72:247–260.
   PubMedGoogle Scholar
• Hollstein, M., D. Sidransky, B. Vogelstein, and C. Harris. 1991. p53 mutations in human cancer. Science 253:49–52.
   PubMed Web of Science ®Google Scholar
• Ishioka, C., C. Engler, P. Winge, Y. X. Yen, M. Engelstein, and S. H. Friend. 1993. Mutational analysis of the carboxy-terminal portion of p53 using both yeast and mammalian assays in vivo. Oncogene 10:1485–1492.
   Google Scholar
• Jackson, P., E. Bos, and A. W. Braithwaite. 1993. Wild-type p53 down-regulates transcription from different virus enhancer/promoters. Oncogene 8:589–597.
   PubMed Web of Science ®Google Scholar
• Jacobson, M. D., J. F. Burne, M. P. King, T. Miyashita, J. C. Reed, and M. C. Raff. 1993. Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA. Nature 361:365–369.
   PubMed Web of Science ®Google Scholar
• Juven, T., Y. Barak, A. Zauberman, D. L. George, and M. Oren. 1993. Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene 8:3411–3416.
   PubMed Web of Science ®Google Scholar
• Kastan, M. B., O. Onyekwere, D. Sidransky, B. Vogelstein, and R. W. Craig. 1991. Participation of p53 in the cellular response to DNA damage. Cancer Res. 51:6304–6311.
   PubMed Web of Science ®Google Scholar
• Kastan, M. B., Q. Zhan, W. S. El-Deiry, F. Carrier, T. Jacks, W. V. Walsh, B. S. Plunkett, B. Vogelstein, and A. J. Fornace, Jr. 1992. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71:587–597.
   PubMed Web of Science ®Google Scholar
• Kern, S. E., J. A. Pietenpol, S. Thiagalingam, A. Seymour, K. W. Kinzler, and B. Vogelstein. 1992. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256:827–830.
   PubMed Web of Science ®Google Scholar
• Knippschild, U., T. Kolzau, and W. Deppert. 1995. Cell-specific transcrip-tional activation of the mdm2-gene by ectopically expressed wild-type form of a temperature-sensitive mutant p53. Oncogene 11:683–690.
   PubMedGoogle Scholar
• Knudson, M., K. Tung, G. Tourtellotte, G. A. J. Brown, and S. J. Korsmeyer. 1995. Bax-deficient mice with lymphoid hyperplasia and male germ cell death. Science 270:96–98.
   PubMed Web of Science ®Google Scholar
• Ko, L. J., and C. Prives. 1996. p53: puzzle and paradigm. Genes Dev. 10:1054–1072.
   PubMed Web of Science ®Google Scholar
• Kobayashi, T., U. Consoli, M. Andreeff, H. Shiku, A. B. Deisseroth, and W. Zhang. 1995. Activation of p21WAF1/Cip1 expression by a temperature-sensitive mutant of human p53 does not lead to apoptosis. Oncogene 11:2311–2316.
   PubMed Web of Science ®Google Scholar
• Krajewski, S., S. Tanaka, S. Takayama, M. Schibler, W. Fenton, and J. C. Reed. 1993. Investigation of the subcellular distribution of the bcl-2 onco-protein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res. 53:4701–4714.
   PubMed Web of Science ®Google Scholar
• Kuerbitz, S. J., B. S. Plunkett, W. V. Walsh, and M. B. Kastan. 1992. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA 89:7491–7495.
   PubMed Web of Science ®Google Scholar
• Lotem, J., and L. Sachs. 1993. Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents. Blood 82:1092–1096.
   PubMed Web of Science ®Google Scholar
• Lowe, S. W., H. E. Ruley, T. Jacks, and D. E. Housman. 1993. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957–967.
   PubMed Web of Science ®Google Scholar
• Lowe, S. W., E. M. Schmitt, S. W. Smith, B. A. Osborne, and T. Jacks. 1993. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature (London) 362:847–852.
   PubMed Web of Science ®Google Scholar
• Lu, X., and D. P. Lane. 1993. Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes? Cell 75:765–778.
   PubMed Web of Science ®Google Scholar
• Ludwig, R. L., S. Bates, and K. H. Vousden. 1996. Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol. Cell. Biol. 16:4952–4960.
   PubMed Web of Science ®Google Scholar
• Maltzman, W., and L. Czyzyk. 1984. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol. Cell. Biol. 4:1689–1694.
   PubMed Web of Science ®Google Scholar
• Miyashita, T., S. Krajewski, M. Krajewska, H. G. Wang, H. K. Lin, D. A. Liebermann, B. Hoffman, and J. C. Reed. 1994. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9:1799–1805.
   PubMed Web of Science ®Google Scholar
• Miyashita, T., and J. Reed. 1995. Tumor suppressor p53 is a direct tran-scriptional activator of the human bax gene. Cell 80:293–299.
   PubMed Web of Science ®Google Scholar
• Oltavi, Z., M. Curt, and S. J. Korsmeyer. 1993. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74:609–619.
   PubMed Web of Science ®Google Scholar
• Ory, K., Y. Legros, C. Auguin, and T. Soussi. 1994. Analysis of the most representative tumor-derived p53 mutants reveals that changes in the protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. EMBO J. 13:3496–3504.
   PubMed Web of Science ®Google Scholar
• Peterson, M. G., N. Tanese, B. F. Pugh, and R. Tjian. 1990. Functional domains and upstream activation properties of cloned human TATA binding protein. Science 248:1626–1630.
   Google Scholar
• Renzing, J., and D. P. Lane. 1995. p53-dependent growth arrest following calcium phosphate-mediated transfection of murine fibroblasts. Oncogene 10:1865–1868.
   PubMedGoogle Scholar
• Rowan, S., R. L. Ludwig, Y. Haupt, S. Bates, X. Lu, M. Oren, and K. H. Vousden. 1996. Specific loss of apoptotic but not cell cycle arrest function in a human tumor derived p53 mutant. EMBO J. 15:827–838.
   PubMed Web of Science ®Google Scholar
• Sabbatini, P., J. Lin, A. J. Levine, and E. White. 1995. Essential role for p53-mediated transcription in E1A-induced apoptosis. Genes Dev. 9:2184–2192.
   PubMed Web of Science ®Google Scholar
• Santhanam, U., A. Ray, and P. B. Sehgal. 1991. Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proc. Natl. Acad. Sci. USA 88:7605–7609.
   PubMed Web of Science ®Google Scholar
• Selvakumaran, M., H. Lin, T. Miyashia, H. G. Wang, S. Krajewski, J. C. Reed, B. Hoffman, and D. Lieberman. 1994. Immediate early up-regulation of bax expression by p53 but not TGFb1: a paradigm for distinct apoptotic pathways. Oncogene 9:1791–1798.
   PubMed Web of Science ®Google Scholar
• Shaulian, E., I. Haviv, Y. Shaul, and M. Oren. 1995. Transcriptional repression by the C-terminal domain of p53. Oncogene 10:671–680.
   PubMedGoogle Scholar
• Symonds, H., L. Krail, L. Remington, M. Saenz-Robles, S. Lowe, T. Jacks, and T. Van Dyke. 1994. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 78:703–711.
   PubMed Web of Science ®Google Scholar
• Vogelstein, B., and K. Kinzler. 1992. p53 function and dysfunction. Cell 70:523–526.
   PubMed Web of Science ®Google Scholar
• Wagner, A. J., J. M. Kokontis, and N. Hay. 1994. Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1. Genes Dev. 8:2817–2830.
   PubMed Web of Science ®Google Scholar
• Wang, E. H., P. N. Friedman, and C. Prives. 1989. The murine p53 protein blocks replication of SV40 DNA in vitro by inhibiting the initiation functions of SV40 large T antigen. Cell 57:379–392.
   PubMed Web of Science ®Google Scholar
• Wang, H.-G., J. A. Milan, A. D. Cox, C. J. Der, U. R. Rapp, T. Beck, H. Zha, and J. C. Reed. 1995. R-ras promotes apoptosis caused by growth factor deprivation via a Bcl-2 suppressable mechanism. J. Cell. Biol. 129:1103–1114.
   PubMed Web of Science ®Google Scholar
• Wang, Y., and C. Prives. 1995. Increased and altered DNA binding of human p53 by S and G2/M but not G1 cyclin-dependent kinases. Nature (London) 376:88–91.
   PubMed Web of Science ®Google Scholar
• White, E. 1996. Life, death, and the pursuit of apoptosis. Genes Dev. 10:1–15.
   PubMed Web of Science ®Google Scholar
• Wu, L., J. H. Bayle, B. Elenbaas, N. P. Pavletich, and A. J. Levine. 1995. Alternatively spliced forms in the carboxy-terminal domain of the p53 protein regulate its ability to promote annealing of complementary single strands of nucleic acids. Mol. Cell. Biol. 15:497–504.
   PubMedGoogle Scholar
• Xiong, Y., G. J. Hannon, H. Zhang, D. Casso, R. Kobayashi, and D. Beach. 1993. p21 is a universal inhibitor of cyclin kinases. Nature (London) 366:701–704.
   PubMed Web of Science ®Google Scholar
• Yeargin, J., and M. Haas. 1995. Elevated levels of wild-type p53 induced by radiolabeling of cells leads to apoptosis or sustained growth arrest. Curr. Biol. 5:423–431.
   PubMed Web of Science ®Google Scholar
• Yonish-Rouach, E., J. Borde, M. Gotteland, Z. Mishal, A. Viron, and E. May. 1994. Induction of apoptosis by transiently transfected metabollically stable wt p53 in transformed cell lines. Cell Death Differ. 1:39–47.
   PubMedGoogle Scholar
• Zauberman, A., Y. Barak, N. Ragimov, N. Levy, and M. Oren. 1993. Sequence-specific DNA binding by p53: identification of target sites and lack of binding to p53-MDM2 complexes. EMBO J. 12:2799–2808.
   PubMed Web of Science ®Google Scholar
• Zauberman, A., A. Lupro, and M. Oren. 1995. Identification of p53 target genes through immune selection of genomic DNA: the cyclin g gene contains two distinct p53 binding sites. Oncogene 10:2361–2366.
   PubMedGoogle Scholar
• Zhan, Q., S. Pan, I. Bae, C. Guillouf, D. A. Liebermann, P. M. O’Conner, and A. J. Fornace, Jr. 1994. Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene 9:3743–3751.
   PubMed Web of Science ®Google Scholar
• Zhang, W., X. Guo, H. Gui-Ying, L. Wen-Biao, J. Shay, and A. Deisseroth. 1994. A temperature-sensitive mutant of human p53. EMBO J. 13:2535–2544.
   PubMedGoogle Scholar